Bristol Myers Squibb

News

Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront.

News

Bristol Myers Squibb is spending big to avoid being left behind in the race to develop a much-touted class of bispecific antibodies for cancer.

News

Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a failed clinical trial.

News

Bristol-Myers Squibb's Camzyos has fallen short in a trial in non-obstructive hypertrophic cardiomyopathy, denting its growth prospects.

News

Bristol-Myers Squibb has claimed its second FDA approval in just a few days for its Opdivo/Yervoy combination, this time in liver cancer.

News

The FDA has approved Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for patients with a particular form of colorectal cancer.